Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2011-04-12
2011-04-12
Lucas, Zachariah (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S184100, C424S204100, C424S281100, C435S235100, C435S236000
Reexamination Certificate
active
07923017
ABSTRACT:
The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus.
REFERENCES:
patent: 5155020 (1992-10-01), Paoletti
patent: 5185146 (1993-02-01), Altenburger
patent: 5494807 (1996-02-01), Paoletti et al.
patent: 5789245 (1998-08-01), Dubensky, Jr. et al.
patent: 6663871 (2003-12-01), McMichael et al.
patent: 6761893 (2004-07-01), Chaplin et al.
patent: 6976752 (2005-12-01), Parish et al.
patent: 7097842 (2006-08-01), Suter et al.
patent: 7189536 (2007-03-01), Chaplin et al.
patent: 7445924 (2008-11-01), Chaplin et al.
patent: 7459270 (2008-12-01), Chaplin et al.
patent: 2002/0106798 (2002-08-01), Robinson et al.
patent: 2003/0044421 (2003-03-01), Emini et al.
patent: 2003/0138454 (2003-07-01), Hill et al.
patent: 2004/0131594 (2004-07-01), McMichael et al.
patent: 2005/0214323 (2005-09-01), Chaplin et al.
patent: 2006/0029619 (2006-02-01), Howley et al.
patent: 2006/0127984 (2006-06-01), Ackermann et al.
patent: 2006/0159699 (2006-07-01), Howley et al.
patent: 2006/0165727 (2006-07-01), Howley et al.
patent: 2006/0280758 (2006-12-01), Chaplin et al.
patent: 2010/0119545 (2010-05-01), Chaplin et al.
patent: 0836648 (1998-04-01), None
patent: 321679 (2003-05-01), None
patent: 1312678 (2003-05-01), None
patent: WO95/22978 (1995-08-01), None
patent: 96/03144 (1996-02-01), None
patent: WO 97/02355 (1997-01-01), None
patent: WO9702355 (1997-02-01), None
patent: WO 97/31119 (1997-08-01), None
patent: WO98/13500 (1998-04-01), None
patent: WO 98/56919 (1998-12-01), None
patent: WO 99/07869 (1999-02-01), None
patent: WO 00 39016 (2000-05-01), None
patent: WO 01 68820 (2001-09-01), None
patent: WO 02/24224 (2002-03-01), None
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmacuetical Compositions Based Thereon, Investigation No. 337-TA-550, Commission Opinion on behalf of the Office of the Secretary, Document ID: 270867, United States International Trade Commission, Washington, D.C., Mar. 6, 2007.
Bowie et al., Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions, 1990, Science, vol. 247, No. 4948, pp. 1306-1310.
Johnston et al., Current Concepts: An HIV Vaccine-Evolving Concepts, 2007, New England Journal Of Medicine, vol. 356, No. 20, pp. 2073-2081.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmacuetical Compositions Based Thereon, Investigation No. 337-TA-550, Commission Opinion on behalf of the Office of the Secretary, Document ID: 270867, United States International Trade Commission, Washington, D.C., Mar. 6, 2007.
Ambrosini et al., Gene Transfer in Astrocytes: Comparison Between Different Delivering Methods and Expression of the HIV-1 Protein Nef, 1999, Journal of Neuroscience Research, vol. 55, pp. 569-577.
Moss et al. “Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.” Advances in Experimentaly Medicine and Biology 397:7-13, 1996.
Wyatt et al (PNAS 101:4590-4595, 2004).
Earl et al (Nature 428:182-185, 2004).
Eo et al, The Journal of Immunology 166:5473-5479, May 2001.
Holzer et al (Journal of Virology 73:4536-4542, 1999).
Antoine et al (Virology 244:365-96, 1998).
Gilbert et al (Biol. Chem. 380:299-303, 1999).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550.Order No. 28: Denying in Part Complainant's Motion for Summary Determination and Denying in Part Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Apr. 18, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Nucleotide alignment of MVA-Antione vs Acambis 3000 MVA vs MVA-BN, Aug. 31, 2005.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Amended Pre-Hearing Brief, United States International Trade Commission, Washington, D.C., May 8, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Opposition to Compainant's Motion for Sanctions, United States International Trade Commission, Washington, D.C., Jul. 7, 2006.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Opposition to Compainant's Motion for Summary Determination of Infringement,10439953.051603 United States International Trade Commission, Washington, D.C.
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Respondent's Rebuttal to Compainant's Proposed Conclusions of Law, United States International Trade Commission, Washington, D.C., Jun. 14, 2006.
In the maater of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Parmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavariian Nordic's Motion for Santions and Memorandum in Support of Its Motion, United States International Trade Commission, Washington, D.C., Jun. 21, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Visuses and Vaccines and Parmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Memorandum in Opposition to Respondent's Motion for Summary Determination, United States International Trade Commission, Washington, D.C., Mar. 30, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Memorandum in Support of Its Motion in Limine, United States International Trade Commission, Washington, D.C., May 1, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant's Post Hearing Brief, United States International Trade Commission, Washington, D.C., Apr. 28, 2006 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant Bavarian Nordic's Motion for Summary Determination of Infringement of the '893 Patent, Its Memorandum of Law in Support of Its Motion, Its Statement of Undisputed Facts in Support of Its Motion and Supporting Exhibits, United States International Trade Commission, Washington, D.C., Mar. 20, 2005 (Public Version).
In the matter of: Certain Modified Vaccinia Ankara (“MVA”) Viruses and Vaccines and Pharmaceutical Compositions Based Thereon, Investigation No. 337-TA-550,Compainant's Post Hearing Reply Brief, United States International Trade Commission, Washington, D.C., Jun. 14, 2006 (Public Version).
Bender, et al., Oral Immunization with a Replication-Deficient Recombinant Vaccinia Virus Protects Mice Against Influenza. (1996) J. Virology, vol. 70(9):6418-6424.
Jax® Mice Data Sheet, Product Information for Stock No. 001913, The Jackson Laboratory, Bar Ha
Chaplin Paul
Howley Paul
Meisinger-Henschel Christine
Bavarian Nordic A/S
Blumel Benjamin P
Law Office of Salvatore Arrigo and Scott Lee, LLP
Lucas Zachariah
LandOfFree
Modified Vaccinia Ankara virus variant does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified Vaccinia Ankara virus variant, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified Vaccinia Ankara virus variant will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712823